Casual Nexus – Episode One: Formulation Development and Clinical Supply of Aseptic Liposomal
Presenters: Iain MacGilp, Ph.D., Director, GMP Production, Curia Amber McFarlane, Head of Formulation Development, Curia Listen in as our experts discuss: The importance of an integrated formulation development and clinical supply function that can support accelerated timelines to clinic, including complex formulations Recent and ongoing experiences in liposomal formulations, with focus on high pressure homogenization Linearity of laboratory to clinical supply scale-up with supporting analytics Broad applicability to variety of product types and presentations (liquid, lyophilized, potent compounds, cytotoxicsView resource
Ready to move from idea to impact?
Whether you have a question for our team or an opportunity you’re eager to pursue, one of our experts can help you get started.Contact Us
More from Curia
Lyophilization: Protecting and preserving biologics
Lyophilization, also known as freeze-drying, is often a crucial step in the manufacturing process of biologics drug products. Biologics are large, complex molecules used to treat various diseases, including cancer, autoimmune disorders, and rare gene...
Rapid discovery and characterization of monoclonal antibodies against the SARS-CoV-2 Delta spike protein
In the fall of 2021, the Delta variant of SARS-CoV-2 was the dominant strain in the US, being both more contagious than previous variants and more likely to lead to “long COVID” than subsequent Omicron variants. Here we describe the discovery and...